Pierre-Henri Storck

USPTO Granted Patents = 38 (Patent Applications = 6)

CIPO Patents = 4

EPO Patents = 15 (Patent Applications = 24)

Average Co-Inventor Count = 8.5

ph-index = 15

Forward Citations = 390(Granted Patents)

Location History:

Rouen, FR (2012 - 2014)
Ramsgate, GB (2012 - 2017)
Kent, GB (2014 - 2023)
Abingdon, GB (2014 - 2024)

Company Filing History:

27 out of 1,149

Vertex Pharmaceuticals, Inc.

patents

11 out of 2,076

Janssen Pharmaceutica Nv

where one patent can have more than one assignee

Years Active: 2012-2025

Loading Chart...

38 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12187731 - Compounds useful as inhibitors of ATR kinase (2025-01-07),

2. 12084438 - GCN2 inhibitors and uses thereof (2024-09-10),

3. 11583524 - Inhibitors of the interaction between MDM2 and P53 (2023-02-21),

4. 11370798 - Compounds useful as inhibitors of ATR kinase (2022-06-28),

5. 11117900 - Compounds useful as inhibitors of ATR kinase (2021-09-14),

6. 10988477 - GCN2 inhibitors and uses thereof (2021-04-27),

7. 10800781 - Compounds useful as inhibitors of ATR kinase (2020-10-13),

8. 10793563 - GCN2 inhibitors and uses thereof (2020-10-06),

9. 10787452 - Compounds useful as inhibitors of ATR kinase (2020-09-29),

10. 10392391 - Compounds useful as inhibitors of ATR kinase (2019-08-27),

11. 10093676 - Compounds useful as inhibitors of ATR kinase (2018-10-09),

12. 9718827 - Compounds useful as inhibitors of ATR kinase (2017-08-01),

13. 9670215 - Compounds useful as inhibitors of ATR kinase (2017-06-06),

14. 9663519 - Compounds useful as inhibitors of ATR kinase (2017-05-30),

15. 9650381 - Compounds useful as inhibitors of ATR kinase (2017-05-16),

Title: Pierre-Henri Storck: Innovator in Pharmaceutical Compounds

Introduction

Pierre-Henri Storck is a distinguished inventor based in Abingdon, GB, known for his significant contributions to the field of pharmaceutical innovations. With an impressive portfolio totaling 27 patents, he has made strides in developing compounds that target critical biological pathways.

Latest Patents

Among his latest patents are notable inventions such as "Compounds useful as inhibitors of ATR kinase." This invention encompasses a range of compounds designed to inhibit ATR protein kinase, along with various pharmaceutically acceptable compositions. The invention not only details the methods for treating diverse diseases, disorders, and conditions but also outlines processes for the preparation of these compounds and their intermediates. Additionally, his patent titled "GCN2 inhibitors and uses thereof" presents compounds and compositions focused on GCN2 inhibition and their therapeutic applications.

Career Highlights

Pierre-Henri has built his career at prominent companies, including Vertex Pharmaceuticals and Merck Patent GmbH. His work at these institutions has propelled pharmaceutical research and created pathways for novel therapies that impact numerous medical fields.

Collaborations

Throughout his career, Pierre-Henri has collaborated with esteemed colleagues including Jean-Damien Charrier and Joanne Louise Pinder. Together, they have contributed to advancing the understanding and application of kinase inhibitors in scientific research and therapeutic contexts.

Conclusion

With a robust patent portfolio and collaborative spirit, Pierre-Henri Storck illustrates the epitome of innovation in the pharmaceutical industry. His dedication to creating beneficial compounds continues to support advancements in medical treatments and research methodologies.

This text is generated by artificial intelligence and may not be accurate.